Physician profile
Josee Smith
NPI 1811571037
$3,362.52
in general payments reported to CMS, 2019-2025
14 companies · $942 in 2025
The $942 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $218 · 2024: $2,078 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937 · Travel and Lodging: $1,101 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.13 |
| Travel and Lodging | $1,101.43 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,718.31 | 2022-2024 | Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $298.24 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $221.55 | 2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $137.65 | 2024 | Tremfya |
| Arcutis Biotherapeutics, INC. | $126.26 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $118.98 | 2025 | |
| Organon LLC | $116.48 | 2025 | Vtama |
| Krystal Biotech INC | $105.97 | 2024 | Vyjuvek |
| Janssen Biotech, INC. | $99.99 | 2025 | Tremfya |
| Eli Lilly and Company | $99.00 | 2025 | |
| Lilly USA, LLC | $97.30 | 2025 | Ebglyss |
| Incyte Corporation | $96.77 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.90 | 2023 | Spevigo |
| Biofrontera INC. | $62.12 | 2025 | Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josee Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.